Naiyer Rizvi

Naiyer Rizvi is a leading clinical investigator of bifunctional antibody therapeutics in lung cancer and other solid tumors at Columbia University, conducting pivotal trials of bispecific antibodies that simultaneously block PD-1 and CTLA-4 or engage T cells with tumor antigens. His clinical research has demonstrated the potential of bispecific checkpoint-blocking antibodies to improve response rates compared to mono-specific checkpoint inhibitors. He has contributed to defining the optimal clinical development strategies for bifunctional antibodies in solid tumor indications.